Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Journal: Molecular cancer therapeutics 20121001
Title: Irreversible protein kinase inhibitors: balancing the benefits and risks.
Journal: Journal of medicinal chemistry 20120726
Title: NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.
Journal: Biochemical and biophysical research communications 20120713
Title: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120701
Title: Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Journal: Journal of medicinal chemistry 20120322
Title: WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
Journal: Laboratory investigation; a journal of technical methods and pathology 20120301
Title: Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
Journal: Nature 20091224
Title: Zhou W, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.Nature. 2009 Dec 24;462(7276):1070-4.
